Hsbc Holdings PLC Boosts Stock Position in Insulet Co. (NASDAQ:PODD)

Hsbc Holdings PLC lifted its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 167,480 shares of the medical instruments supplier's stock after purchasing an additional 8,171 shares during the period. Hsbc Holdings PLC owned 0.24% of Insulet worth $43,712,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of PODD. Stifel Financial Corp increased its position in Insulet by 167.2% during the 4th quarter. Stifel Financial Corp now owns 28,126 shares of the medical instruments supplier's stock valued at $7,343,000 after purchasing an additional 17,599 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Insulet by 65.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,332 shares of the medical instruments supplier's stock worth $870,000 after buying an additional 1,323 shares during the period. Sharpepoint LLC bought a new position in Insulet during the fourth quarter worth $2,091,000. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in Insulet by 17.5% in the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 13,661 shares of the medical instruments supplier's stock valued at $3,566,000 after buying an additional 2,031 shares during the period. Finally, MetLife Investment Management LLC lifted its holdings in Insulet by 1.1% in the fourth quarter. MetLife Investment Management LLC now owns 21,638 shares of the medical instruments supplier's stock valued at $5,649,000 after buying an additional 233 shares during the period.

Insulet Stock Down 0.6 %

Shares of PODD traded down $1.59 during trading hours on Thursday, reaching $250.71. 140,433 shares of the stock traded hands, compared to its average volume of 713,786. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The stock has a fifty day simple moving average of $258.37 and a 200 day simple moving average of $261.95. The company has a market cap of $17.61 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 3.62 and a beta of 1.30. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, equities analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on PODD. TD Cowen upped their target price on Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a research report on Friday, January 3rd. Raymond James reaffirmed an "outperform" rating and set a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. StockNews.com lowered shares of Insulet from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Citigroup increased their target price on shares of Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Finally, Wolfe Research downgraded shares of Insulet from an "outperform" rating to a "peer perform" rating in a research note on Tuesday. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $293.94.

Insider Activity

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. This represents a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.47% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.